We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardinal Health (CAH) Laps the Stock Market: Here's Why
Read MoreHide Full Article
Cardinal Health (CAH - Free Report) closed the most recent trading day at $161.89, moving +1.72% from the previous trading session. This change outpaced the S&P 500's 0.79% gain on the day. At the same time, the Dow added 1.01%, and the tech-heavy Nasdaq gained 1.15%.
Prior to today's trading, shares of the prescription drug distributor had gained 6.85% outpaced the Medical sector's gain of 3.99% and the S&P 500's gain of 1.27%.
The investment community will be closely monitoring the performance of Cardinal Health in its forthcoming earnings report. The company is scheduled to release its earnings on October 30, 2025. It is anticipated that the company will report an EPS of $2.21, marking a 17.55% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $59.05 billion, indicating a 12.96% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $9.45 per share and revenue of $249 billion. These totals would mark changes of +14.68% and +11.87%, respectively, from last year.
Any recent changes to analyst estimates for Cardinal Health should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% lower. Currently, Cardinal Health is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, Cardinal Health is currently trading at a Forward P/E ratio of 16.85. This expresses a premium compared to the average Forward P/E of 13.51 of its industry.
We can additionally observe that CAH currently boasts a PEG ratio of 1.35. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Medical - Dental Supplies industry held an average PEG ratio of 1.64.
The Medical - Dental Supplies industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 98, finds itself in the top 40% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CAH in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cardinal Health (CAH) Laps the Stock Market: Here's Why
Cardinal Health (CAH - Free Report) closed the most recent trading day at $161.89, moving +1.72% from the previous trading session. This change outpaced the S&P 500's 0.79% gain on the day. At the same time, the Dow added 1.01%, and the tech-heavy Nasdaq gained 1.15%.
Prior to today's trading, shares of the prescription drug distributor had gained 6.85% outpaced the Medical sector's gain of 3.99% and the S&P 500's gain of 1.27%.
The investment community will be closely monitoring the performance of Cardinal Health in its forthcoming earnings report. The company is scheduled to release its earnings on October 30, 2025. It is anticipated that the company will report an EPS of $2.21, marking a 17.55% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $59.05 billion, indicating a 12.96% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $9.45 per share and revenue of $249 billion. These totals would mark changes of +14.68% and +11.87%, respectively, from last year.
Any recent changes to analyst estimates for Cardinal Health should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% lower. Currently, Cardinal Health is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, Cardinal Health is currently trading at a Forward P/E ratio of 16.85. This expresses a premium compared to the average Forward P/E of 13.51 of its industry.
We can additionally observe that CAH currently boasts a PEG ratio of 1.35. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Medical - Dental Supplies industry held an average PEG ratio of 1.64.
The Medical - Dental Supplies industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 98, finds itself in the top 40% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CAH in the coming trading sessions, be sure to utilize Zacks.com.